CRVO — CervoMed Inc.

CervoMed Inc. , a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.

Sector

Healthcare

Industry

Biotechnology

Market Cap

$36.5M

P/E Ratio

-1.35

Beta

-5.04

52-Week Range

3.51-13.13

Dividend Yield

$0.00

CEO

John J. Alam

Employees

15

IPO Date

May 23, 2008

Exchange

NASDAQ